| Literature DB >> 24734056 |
Poonam Inamdar1, Shashikant Bhandari1, Bhagyashri Sonawane1, Asha Hole1, Chintamani Jadhav1.
Abstract
The urgent need of neuraminidase inhibitors (NI) has provided an impetus for understanding the structure requisite at molecular level. Our search for selective inhibitors of neuraminidase has led to the identification of pharmacophoric requirements at various positions around acyl thiourea pharmacophore. The main objective of present study is to develop selective NI, with least toxicity and drug like ADMET properties. Electronic, Steric requirements were defined using kohnone nearest neighbour- molecular field analysis (kNN-MFA) model of 3D-QSAR studies. Results generated by QSAR studies showed that model has good internal as well as external predictivity. Such defined requirements were used to generate new chemical entities which exhibit higher promising predicted activities. To check selective binding of designed NCE's docking studies were carried out using the crystal structure of the neuraminidase enzyme having co-crystallized ligand Oseltamivir. Thus, molecular modelling provided a good platform to optimize the acyl thiourea pharmacophore for designing its derivatives having potent anti-viral activity.Entities:
Keywords: Anti-influenza agents; Drug design; Molecular Modelling; Neuraminidase Inhibitors; Optimization
Year: 2014 PMID: 24734056 PMCID: PMC3985258
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Uni-Column statistics for Training and Test set of Compounds
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| -0.17912 | -0.10595 | 1.09691 | 0.4437 | -1.2672 | -0.8567 |
a Higher the value of pIC50 (Greater +ve-value), higher is the potency.
Training set and Test Set from selected series of compounds for QSAR study with Acyl Thiourea pharmacophore
| 1) Training set molecules | ||||
|---|---|---|---|---|
|
|
|
|
|
|
| 1 | 4-Ethoxy-6-Methyl pyrimidine | 5-(2-chlorophenyl)-2-furyl | 1.65 | -0.21748 |
| 2 | 4,6-diethoxy pyrimidine | 5-(2-chlorophenyl)-2-furyl | 0.08 | 1.09691 |
| 3 | 4-Hydroxy-6-Methyl pyrimidine | 5-(2-chlorophenyl)-2-furyl | 0.32 | 0.49485 |
| 4 | 4,6-dimethoxy pyrimidine | 5-(2-chlorophenyl)-2-furyl | 1.77 | -0.24797 |
| 5 | 4,6-dichloro pyrimidine | 5-(2-chlorophenyl)-2-furyl | 14.5 | -1.16137 |
| 6 | 4,6-dichloro pyrimidine | 5-(4-nitrophenyl)-2-furyl | 1.66 | -0.22011 |
| 7 | t-butyl | 5-(4-nitrophenyl)-2-furyl | 1.30 | -0.11394 |
| 8 | t-butyl | Phenyl | 1.79 | -0.25285 |
| 9 | t-butyl | Methyl | 1.83 | -0.26245 |
| 10 | t-butyl | (2,4-Dichloro-Phenyl)-OCH2 | 1.67 | -0.22272 |
| 11 | t-butyl | 2,6-Difluoro-Phenyl | 1.43 | -0.15534 |
| 12 | t-butyl | 2-Methyl-1-(4-Chloro-Phenyl)-Propane | 1.35 | -0.13033 |
| 13 | t-butyl | 3-(2, 2-dichloro ethenyl)-2,2-dimethyl cyclopropyl. | 0.26 | 0.58503 |
| 14 | 4-Methoxy-6-chloro pyrimidine | 5-(2-chlorophenyl)-2-furyl | 1.29 | -0.11059 |
| 15 | 4-Methyl-6-Hydroxy pyrimidine | 6-Chloro-3-Pyridine | 8.58 | -0.93349 |
| 16 | 4,6-dimethoxy pyrimidine | 5,6-Dichloro-3- Pyridine | 18.5 | -1.26717 |
| 17 | 4,6-dimethyl pyrimidine | Phenyl | 2.1 | -0.32222 |
| 18 | 4,6-diethoxy pyrimidine | 2-Methyl-1-(4-Chloro-Phenyl)-Propane | 0.31 | 0.50864 |
| 19 | 4,6-dimethoxy pyrimidine | 3-(2-chloro-3,3,3-trifluropropenyl)-2,2-dimethyl cyclopropyl | 0.97 | 0.01323 |
| 20 | 4,6-dimethyl pyrimidine | 3-(2-chloro-3,3,3-trifluropropenyl)-2,2-dimethyl cyclopropyl | 0.58 | 0.23657 |
| 21 | 4,6-dimethyl pyrimidine | 2-Fluoro-4-Chloro-Phenyl | 1.36 | -0.133539 |
| 22 | 4-Methoxy-6-chloro pyrimidine | 2-Fluoro-4-Chloro-Phenyl | 5.1 | -0.70757 |
| 2) Test set molecules. | ||||
| 1 | 4-Hydroxy-6-Methyl pyrimidine | 5-(4-nitrophenyl)-2-furyl | 0.36 | 0.4437 |
| 2 | t-butyl | 5-(2-Chloro-Phenyl)-2-Furyl | 1.42 | -0.152288 |
| 3 | t-butyl | 3-(2-chloro-3,3,3-trifluropropenyl)-2,2-dimethyl cyclopropyl | 0.51 | 0.29243 |
| 4 | 4-Methoxy-6-methyl pyrimidine | 5-(4-nitrophenyl)-2-furyl | 1.22 | -0.08636 |
| 5 | 4,6-dimethyl pyrimidine | 2-Chloro-3- Pyridine | 7.19 | -0.856729 |
| 6 | 4,6-dimethoxy pyrimidine | (2,4-Dichlorophenyl)-OCH2 | 1.89 | -0.276462 |
Figure 1Acyl thiourea template
Figure 2Alignment of Substituted Acyl Thiourea Derivatives using template based alignment method.
Figure 3Most potent Compound from selected series
Prediction of ADMET properties
|
|
|
|
|
|
|---|---|---|---|---|
| R-7 | 331.345 | -2 | 78.416 | 3 |
| R-8 | 388.354 | -2 | 48.485 | 2 |
| Peramivir | 328.411 | -2 | 29.001 | 3 |
| R-4 | 358.371 | -2 | 73.409 | 4 |
| R-10 | 373.383 | -2 | 73.351 | 2 |
| R-9 | 329.373 | -2 | 84.192 | 3 |
| R-2 | 388.354 | -2 | 68.372 | 3 |
| R-5 | 358.371 | -2 | 43.878 | 3 |
| Oseltamivir | 312.408 | -1 | 68.391 | 3 |
Statistical results of 3D QSAR generated by SA kNN MFA method for Acyl Thiourea Derivatives
|
|
|
|
|
|
|---|---|---|---|---|
|
| 0.7697 | 0.2811 | 2 | 0.2972 |
|
| S-333(-0.0053,0.0041) | |||
|
| E-449(0.0749,0.0796) | |||
|
| H-1047(0.3218,0.3622) | |||
|
| 24 | |||
Figure 5Stereo view of the molecular rectangular field grid generated around the superposed molecular units of Acyl Thiourea series using SA kNN-MFA Model
Figure 6Important structural features for potent inhibitor and corresponding neuraminidase residues (23)
Figure 7Diagram of neuraminidase sites S1-S4 and important nearby residues (25).
Figure 8Pharmacophore Requirement of Acyl thiourea Derivatives Generated for Selective Inhibition of neuraminidase for anti-influenza activity
Figure 9Template A
Figure 10Template B
Figure 11Designed template with active binding site
Structures of designed compounds on the basis of template B with their predicted activity.
|
|
|
|
|
|
|---|---|---|---|---|
| R-1 | 4-nitrophenyl | 4-methoxyphenyl | 0.8564 | ADRXWS (6) |
| R-2 | 4-nitrophenyl | 4-nitrophenyl | -0.3876 | ADRXWS (6) |
| R-3 | Benzyl | 4-hydroxyphenyl | 0.9765 | ADRXWS (6) |
| R-4 | 3-aminophenyl | 4-nitrophenyl | 0.8450 | ADRXWS (6) |
Structures of designed compounds on the basis of template A with their predicted activity.
|
|
|
|
|
|
|---|---|---|---|---|
| R-5 | 3-nitro phenyl | 3-carboxy | -0.03206 | ADRXWS (6) |
| R-6 | 2-hydroxy phenyl | 3-carboxy | -0.06934 | ADRXWS (6) |
| R-7 | 2-hydroxy phenyl | 3-hydoxy phenyl | -0.156 | ADRXWS (6) |
| R-8 | 4-nitrophenyl | 3-carboxy phenyl | -0.18876 | ADRXWS (6) |
| R-9 | Benzyl | 3-hydoxy phenyl | -0.38875 | ADRXWS (6) |
| R-10 | 4-methoxy | 3-carboxy | -0.39318 | ADRXWS (6) |
Results of Molecular Docking Studies performed using extra precision mode of Glide (34).
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| R-7 | -5.98 | -51.6 | 3 | 220 | 12 | 3 |
| R-8 | -5.58 | -50.5 | 4 | 233 | 10 | 3 |
| Peramivir | -5.53 | -45.5 | 7 | 278 | 14 | 2 |
| R-4 | -5.14 | -47.3 | 2 | 241 | 7 | 1 |
| R-10 | -5.07 | -43.2 | 8 | 150 | 9 | 2 |
| R-9 | -4.83 | -47.9 | 2 | 210 | 9 | 2 |
| R-2 | -4.79 | -41.2 | 3 | 234 | 11 | 1 |
| R-5 | -4.58 | -47..3 | 3 | 134 | 6 | 1 |
| Oseltamivir | -4.57 | -49.3 | 4 | 266 | 8 | 1 |
| R-3 | -4.27 | -51.3 | 2 | 233 | 6 | 0 |
| R-6 | -3.91 | -58.0 | 6 | 167 | 7 | 0 |
| R-1 | -2.74 | -2.74 | 2 | 173 | 6 | 0 |
aHydrogen Bond.
bVan der Waals forces.
Key interactions with distances and involved groups
|
|
|
|
|
|
|---|---|---|---|---|
| R-7 | Glu 119 | 1.793 | -NH | -COOH |
| R-8 | Glu 119 | 1.747 | -NH | -COOH |
| Peramivir | Trp 178 | 1.960 | -NH of guanidine | -C=O |
| R-4 | Asp 151 | 2.068 | -NH | -C=O |
| R-10 | Asp 151 | 1.851 | -NH | -C=O |
| R-9 | Glu 119 | 1.938 | -NH | -C=O |
| R-2 | Asn 294 | 2.3 | O of NO2 | -NH |
| R-5 | Asp 151 | 2.213 | -NH | -C=O |
| Oseltamivir | Arg 152 | 2.18 | -C=O of COCH3 | -NH |
Figure 12Hydrogen bond interaction of R-7
Figure 13Hydrogen bond interaction of R-10
Figure 14Hydrogen bond interaction of Oseltamivir
Figure 15Hydrogen bond interaction of Peramivir